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Endovascular Interventions for Stroke*Gregory W. Albers, MD,y Jonathan L. Halperin, MDzSEE PAGE 2498W hether interventional approaches tostroke neurology have lagged behindthose aimed at heart attack—for reasons
biological or practical—are topics for another day.
However, the balance has changed. Tissue plasmin-
ogen activator (tPA) was ﬁrst approved in the United
States for intravenous administration to patients
with acute stroke in 1996 (1), and a study for
catheter-directed intra-arterial infusion of a thrombo-
lytic agent for this indication was ﬁrst published in
1998 (2). The ﬁrst positive randomized controlled
study using mechanical thrombectomy devices for
stroke came from the Netherlands just last year
(3), and results from 4 additional trials published
in 2015 support combined treatment with tPA and
catheter-based thrombectomy (4–7). In the recent
positive stroke trials, removable devices consisting
of self-expanding, clot-retrieving stents achieved
higher rates of recanalization than earlier methods
of thrombus extraction, representing the ﬁrst effec-
tive new treatment for stroke in nearly 20 years.
The measures employed in these studies have length-
ened the time-to-treatment window and help guide
the selection of patients who beneﬁt most from
acute endovascular intervention. With absolute bene-
ﬁts substantially greater than systemic intravenous*Editorials published in the Journal of the American College of Cardiology
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tPA and endovascular therapy have improved out-
comes for selected patients who receive endovascular
treatment within 6 h of symptom onset.The meta-analysis of endovascular stroke trials by
Elgendy et al. (8) presented in this issue of the
Journal summarizes the recent series of achieve-
ments that collectively represent a landmark in stroke
therapy. As with any meta-analysis of heterogeneous
trials, it provides cohesiveness by blurring some of
the inherent differences among the component
studies. The investigators included all randomized
trials of endovascular stroke therapy except the Ital-
ian SYNTHISIS (A Randomized Controlled Trial on
Intra-Arterial Versus Intravenous Thrombolysis in
Acute Ischemic Stroke) (9), which prohibited intra-
venous thrombolysis in the group assigned to endo-
vascular therapy per protocol, and the lack of beneﬁt
associated with endovascular therapy in that study is
noteworthy. Three of the trials included in the anal-
ysis (MR RESCUE [Mechanical Retrieval and Recana-
lization of Stroke Clots Using Embolectomy], IMS III
[Third Interventional Management of Stroke], and
THERAPY [Randomized, Concurrent Controlled Trial
to Assess the Penumbra System’s Safety and Effec-
tiveness in the Treatment of Acute Stroke]) evaluated
mainly ﬁrst-generation thrombectomy devices and
did not ﬁnd a statistically signiﬁcant difference be-
tween endovascular and medical therapies. The IMS
III trial was stopped because of futility after enroll-
ment of 656 patients (10). Similarly, MR RESCUE (11)
failed to demonstrate efﬁcacy for endovascular ther-
apy, and the THERAPY trial was halted prematurely
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2507once announcement of positive results from other
trials disturbed clinical equipoise. In contrast, trials
that predominantly or exclusively involved stent
retrievers exhibited substantially higher reperfusion
rates and better clinical outcomes than those ach-
ieved with the ﬁrst-generation devices. Each had
statistically signiﬁcant risk ratios (RR) of 1.6 to
1.8 with endovascular treatment (indicating the
favorable outcome rate was approximately 1.7-fold
higher in the endovascular arms of the studies).
Therefore, the beneﬁt of modern endovascular ther-
apy with stent retrievers is likely greater than the
overall RR of 1.45 derived by the meta-analysis.
In contrast to the consistent beneﬁt of mechanical
thrombectomy in patients with acute stroke, studies
of primary revascularization in patients with ST-
segment elevation acute myocardial infarction
(STEMI) have found that thrombectomy before an-
gioplasty—whether the technology involves thrombus
aspiration or rheolytic thrombectomy—has not gen-
erally been associated with beneﬁt compared with
primary percutaneous coronary intervention (PCI)
alone (12–16). Among others, the investigators of the
current meta-analysis assessed the role of aspiration
thrombectomy before primary PCI in recent random-
ized trials, and concluded that thrombus removal
was not associated with clinical beneﬁt and might
increase the risk of stroke (17).FIGURE 1 New Randomized Clinical Trials of Endovascular Therapy:
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Results of recent randomized endovascular stroke trials that predominan
each trial who achieved a good clinical outcome (modiﬁed Rankin score o
for each study. The differences in brain imaging methodology used to s
MR ¼ magnetic resonance; MR CLEAN ¼ Multicenter Randomized Clinic
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Solitaire FRWith the Intention for Thrombectomy as Primary Endovascular
Revascularization with Solitaire FR Device versus Best Medical Therapy in
Occlusion Presenting within Eight Hours of Symptom Onset.Primary angioplasty in vessels with large thrombus
burden is associated with greater risks of distal
embolization, no-reﬂow phenomenon, transmural
myocardial necrosis, stent thrombosis, and major
adverse cardiac events, including mortality (18–22),
yet routinely preceding these interventions with
thrombectomy was not associated with improved
short- or long-term outcomes in subgroup analyses of
the TASTE (Thrombus Aspiration in ST-Elevation
Myocardial Infarction in Scandinavia) (13) and TOTAL
(Trial of Routine Aspiration Thrombectomy with PCI
versus PCI Alone in Patients with STEMI) (12) trials. It
is unclear whether the difﬁculty is related to ways in
which in the myocardial microcirculation are differ-
entially affected by these interventional technologies
or whether similar processes are at work in the brain.
Whatever mechanisms are involved, the evolution of
interventional technology for acute stroke manage-
ment has heretofore followed the path paved by
frontline management of patients with acute STEMI,
and the roads may now diverge. Considerable het-
erogeneity in clinical presentation of these acute
ischemic syndromes contributes to the challenge of
case selection for implementation of available revas-
cularization modalities.
In the acute stroke stent retriever trials, clinical
outcomes differed considerably although patient age
and initial stroke severity were similar. This could beImaging Selection
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elect eligible patients is highlighted. CT ¼ computed tomography;
al Trial of Endovascular Treatment for Acute Ischemic Stroke in the
erior Circulation Proximal Occlusion with Emphasis on Minimizing CT
lysis in Emergency Neurological Deﬁcits–Intra-arterial; SWIFT PRIME ¼
Treatment for Acute Ischemic Stroke; REVASCAT¼Randomized Trial of
the Treatment of Acute Stroke Due to Anterior Circulation Large Vessel
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2508related to various imaging criteria employed for
subject inclusion, based on the dual need to identify
large vessel occlusion and exclude extensive cerebral
infarction. In recent trials, computed tomographic
(CT) angiography or magnetic resonance (MR) angi-
ography was generally required to document large
vessel occlusion. In 2 early, negative trials (IMS III
and SYNTHESIS), CT or MR angiography was not
required, which compromised the power of the
studies because the objective of endovascular therapy
is to overcome target vessel occlusion. Exclusion of
patients with early ischemic parenchymal injury
based on imaging also varied between trials. Among
the newer trials, MR CLEAN (Multicenter Randomized
Clinical Trial of Endovascular Treatment for Acute
Ischemic Stroke in the Netherlands) (3) used brain
imaging solely to exclude patients with brain hem-
orrhage. Perhaps as a result, favorable clinical out-
comes were relatively uncommon in both the
endovascular and the control arms; only 33% of the
endovascular patients were left with only slight or
no disability at 3 months (Figure 1). In the Spanish
REVASCAT (Randomized Trial of Revascularization
with Solitaire FR Device versus Best Medical Therapy
in the Treatment of Acute Stroke Due to Anterior
Circulation Large Vessel Occlusion Presenting within
Eight Hours of Symptom Onset) study (7), patients
with evidence of a substantial volume of early
ischemic brain injury as assessed by the ASPECTS
(Alberta Stroke Program Early CT Score) CT score were
excluded from enrollment, and favorable outcomes
were more frequent than in MR CLEAN. The Canadian
ESCAPE (Endovascular Treatment for Small Core and
Anterior Circulation Proximal Occlusion with Em-
phasis on Minimizing CT to Recanalization Times)
trial (6) excluded patients with low ASPECTS scores
and those with poor collateral ﬂow evident on CT
angiography, and 53% of patients in the endovascular
group were left without signiﬁcant functional
disability. The North American/European SWIFT-
PRIME (Solitaire FR With the Intention for Throm-
bectomy as Primary Endovascular Treatment for
Acute Ischemic Stroke) (5) and Australian EXTEND-IA
(Extending the Time for Thrombolysis in EmergencyNeurological Deﬁcits–Intra-arterial) studies (4) used
automated analysis of CT or MRI perfusion images to
identify patients with salvageable brain regions and
relatively small volumes of irreversibly injured
ischemic core tissue. Perhaps as a result, patients in
these trials enjoyed the highest rates of favorable
functional outcomes following endovascular therapy
(60% and 71%) and substantial absolute risk re-
ductions compared with those managed with intra-
venous tPA alone (Figure 1). Patients in the control
groups who were treated with intravenous tPA also
had more favorable outcomes than those in the
other trials, which suggested that the perfusion
imaging approach was useful in identifying patients
with more favorable outlooks with either intrave-
nous or intra-arterial reperfusion.
The majority (>90%) of patients encompassed by
the meta-analysis received endovascular therapy
within 6 h of symptom onset. In more recent trials,
greater emphasis was placed on workﬂow improve-
ments to abbreviate the interval between arrival at the
hospital emergency department and initiation of
reperfusion. For example, in SWIFT PRIME, femoral
puncture occurred a median of 224 min after symptom
onset and a median of 90 min after arrival. Although
these metrics represent substantial improvements
over those in earlier stroke trials, the elapsed times
are considerably longer than typically achieved in
centers that provide catheter-based reperfusion for
acute STEMI. However, to become the new standard
of care for patients with ischemic stroke due to large
artery occlusion, effective implementation of this
approach requires the evolution of systems of acute
stroke care to route appropriate patients to facilities
capable of expedient delivery of all validated tech-
nologies. Further efforts to shorten the interval be-
tween emergency department arrival and treatment
hold the promise of even better outcomes.
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